Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics
Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection
Ligand Reports Fourth Quarter and Full Year 2015 Financial Results
Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics
Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th
Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions
Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock
RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs
Ligand Provides Highlights from Today’s Analyst Day Event
Ligand Reports Third Quarter 2015 Financial Results
Ligand to Report Third Quarter Results on November 9th
Ligand to Host Analyst Day on November 18th in New York City
Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689
